17 recruiting, 10 not yet recruiting, 3 enrolling by invitation. 9 Phase 2, 8 Phase 1, 3 Early Phase 1, 3 Not applicable.
Follow Urothelial Carcinoma (UC): new trials by email Literature Review of Urothelial Carcinoma (UC) trials Research Report on Urothelial Carcinoma (UC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Sutro Biopharma, Inc. | 285 | 2026-09-14 | 2026-09-08 |
| Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR) enfortumab vedotin (EV), PEMBROLIZUMAB (alone or when added to a regimen above), Neuridase - Urothelial Carcinoma (UC), Peripheral Nerve Disease | Not applicable | Not yet recruiting | University of Florence | 40 | 2026-09-01 | 2026-06-08 |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors BL-M09D1 - Urothelial Carcinoma (UC), Solid Tumors | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 42 | 2026-09-01 | 2026-09-23 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples TTP-ICG fluorescent probe - Bladder Cancer (BC), Urothelial Carcinoma (UC) | Phase 2 | Recruiting | Yunnan Cancer Hospital | 30 | 2026-08-01 | 2026-09-30 |
| A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors HLX18, OPDIVO® - Esophageal and/or Cardia Cancer, Melanoma | Phase 1 | Recruiting | Shanghai Henlius Biotech | 174 | 2026-07-15 | 2026-07-27 |
| A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma AK146D1 for injection, AK112 Injection - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-06-22 | 2026-06-09 |
| An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Zanidatamab - Neoplasms, Solid Tumors | Phase 2 | Not yet recruiting | Haihua Yuan | 10 | 2026-06-15 | 2026-06-08 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation - Bladder Tumors, Bladder Tumor | Phase 1 | Not yet recruiting | Juan Luis Vásquez | 20 | 2026-06-01 | 2026-04-29 |
| Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC) | Not yet recruiting | Assiut University | 100 | 2026-05-01 | 2026-04-13 | |
| 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors 18F-T2 PET/CT - Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC) | Not applicable | Recruiting | Peking University First Hospital | 200 | 2026-04-27 | 2026-05-14 |
| Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging Bladder Cancer, Urothelial Carcinoma (UC) | Recruiting | Oslo University Hospital | 150 | 2026-04-22 | 2026-05-22 | |
| Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 - Urothelial Carcinoma (UC) | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 10 | 2026-04-13 | 2026-06-03 |
| Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma | Recruiting | Ruijin Hospital | 477 | 2026-04-05 | 2026-10-22 | |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics Urothelial Carcinoma (UC), HER2 | Enrolling by invitation | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4000 | 2026-03-02 | 2026-03-06 | |
| Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma Multi-Component Liquid Biopsy for Urothelial Carcinoma - Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer | Recruiting | Tianjin Medical University Second Hospital | 300 | 2026-03-01 | 2026-03-02 | |
| Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA SBRT - Bladder Cancer, Urothelial Carcinoma (UC) | Not applicable | Recruiting | Istituto Clinico Humanitas | 44 | 2026-02-16 | 2026-04-30 |
Showing 20 of 30. Sign in to see all of them.
Carcinoma, Transitional Cell (30) · Urinary Bladder Neoplasms (10) · Breast Neoplasms (6) · Colorectal Neoplasms (6) · Head and Neck Neoplasms (6) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Endometrial Neoplasms (5) · Pancreatic Neoplasms (5) · Uterine Cervical Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Disease (3) · Mesothelioma (3) · Neoplasms (3)
Carcinoma (30) · Neoplasms by Histologic Type (30) · Neoplasms, Glandular and Epithelial (30) · Neoplasms (27) · Neoplasms by Site (21) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18) · Male Urogenital Diseases (15) · Urologic Diseases (14) · Urologic Neoplasms (14) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11)
pembrolizumab (3) · Fluorodeoxyglucose F18 (2) · Nivolumab (2) · enfortumab vedotin (2) · Docetaxel (1) · Injections (1) · Ipilimumab (1) · Prednisone (1) · Single Person (1) · relatlimab (1) · zanidatamab (1)
Affiliated Hospital of Jiangnan University (2) · Haihua Yuan (2) · AZ Sint-Lucas Gent (1) · Akeso (1) · Assiut University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Convergent Genomics, Inc. (1) · Exelixis (1) · Henan Provincial People's Hospital (1) · IDEAYA Biosciences (1) · IRCCS San Raffaele (1) · Istituto Clinico Humanitas (1) · Juan Luis Vásquez (1) · Lumara Bio Oncologics GmbH (1) · Martin Huellner (1)
China (12) · United States (5) · Italy (3) · Australia (2) · Belgium (2) · France (2) · Switzerland (2) · Austria (1) · Germany (1) · Israel (1) · New Zealand (1) · Norway (1) · Poland (1) · Puerto Rico (1) · South Korea (1)
Andreas Habberstad, MD, PhD (1) · Daniel Araujo, MD (1) · Edward Chan, MD (1) · Jennifer Oliver (1) · Meng Liu (1) · Zhifeng Wang, PhD (1)
2023 (2)